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Summary. The occurrence of intimal hyperplasia after 
vascular surgery is an ongoing concern in current 
clinical practice. Arnong the many factors involved in 
the development of this pathology, platelet adhesion and 
myointimal proliferation play a major role. Both these 
processes are mediated by integrins (mainly a v P 3  
integrins). Over the past years, severa1 substances have 
been designed to delay or inhibit the cell proliferation 
that leads to hyperplasia and mainly include monoclonal 
antibodies directed against integrins. The aim of the 
present study was to evaluate the effects of an antibody 
denoted P37 (anti B3 integrin) on human smooth muscle 
cells (SMC) and its role in blocking the 83 subunit. To 
this end, SMC from human umbilical artery were 
cultured in the presence or absence of the cell substrate 
vitronectin (VN) and incubated with P37. After 4 days of 
treatment, determination was made of cell proliferation 
and migration. Smooth muscle cells grown on VN 
showed increased proliferation and migration compared 
to control VN-free cultures. However, the presence of 
P37 in the culture medium inhibited proliferation and 
reduced migration. Combined treatment with VN and 
P37 led to improved proliferation but VN was unable to 
reverse the effects on migration observed in the former 
cultures. Results suggest that in vitro, P37 is capable of 
blocking human SMC 83 integrins and thus impedes cell 
proliferation and migration These findings may have 
clinical implications related to modulation of the 
development of hyperplasia. 
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The  appearance of intimal hyperplasia is  a 
phenomenon observed in clinical practice after 
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reparative vascular surgery including prosthesis implant 
or balloon catheter procedures. The excessive cell 
proliferation that occurs in this pathology often leads to 
the appearance of thrombi or to restenosis and hence to 
the failure of the surgical procedure. It is currently 
known that many factors, besides platelets, muscle and 
endothelial cells, are also responsible for intimal 
progression, including molecules of the extracellular 
matrix such as adhesion molecules and their receptors. 
Consequently, it is interactions between cells and matrix 
components that are responsible for the development of 
a myointimal layer and the appearance of immune 
reactions, thrombosis and vessel damage (Schwartz, 
1997). 
To date, severa1 theories have been developed to 
explain neointimal formation although it would appear 
that the proliferation and migration of smooth muscle 
cel ls  (SMC) i s  most likely to contribute to the 
progression of hyperplasia (deRuiter et al., 1997; 
Majesky and Schwartz, 1997). For SMC to migrate and 
proliferate, it i s  necessary that they interact with 
different extracellular matrix proteins, which mainly 
include osteopontin and integrins. 
Osteopontin is expressed at sites where there is 
tissue remodelling (Thager et al., 1995). This molecule 
has been shown to inhibit in vitro and in vivo cell 
migration following angioplasty using a balloon catheter 
(Liaw et al., 1997). 
Integrins are a family of heterodimeric glycoprotein 
subunits designated a and B. The B3 subunits mediate 
important interactions between cells and glycoproteins in 
response to vascular damage (Shattil, 1995). Further, the 
subunits that form integrin a v $ 3  (the vitronectin 
receptor, VN) are commonly associated with SMC 
migration phenomena. In normal conditions, the avP3 
integrin molecule is restricted to the media. Moreover, in 
atherosclerotic plaques and in certain vascular lesions, it 
has been shown to colocate with SMC (Iioshiga et al., 
1995) and has therefore been related to different vascular 
diseases. 
In current clinical practice, monoclonal antibodies 
raised against integrin receptors have proved to be of 
great use after surgical procedures such as angioplasty or 
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vascular repair (Choi et al., 1994; Matsuno et al., 1994; 
Tam et al., 1998). However, only the so-called ReoPro 
antibody (abciximab) has been shown to be efficient 
againstthe integrins'a11bB3 and a v p 3  (Coller et al., 
1991). 
~ e c e n t  in v i v o  experiments performed in our 
laboratory using a new antibody, P37, directed against 
the 101-109 aminoacid sequence of the B3 subunit, 
demonstrated its efficiency in delaying the appearance of 
intima1 hyperplasia through the effective inhibition of 
platelet thrombosis (Bujan et al., 1997). With the aim of 
evaluating the efficiency of the action of this antibody on 
human SMC and its ability to block the B3  subunit of 
avp3 integrin, we developed an in vitro model using a 
vitronectin (VN) substrate for SMC cultured in the 
presence of the P37 antibody. 
Materials and methods 
lsolation and culture of SMC 
Segments of human umbilical cord artery were 
flushed several times with MEM under sterile conditions 
and then longitudinally cut open. After removal of the 
endothelial and adventitial layers by scraping, the media1 
layer was cut into small explants that were subjected to 
digestion in a 0.1% type 1 collagenase solution 
(Worthington) in MEM (1 h at 3 7  "C). Cells were 
subsequently cultivated in F-12 medium (GIBCO BRL) 
containing 2 mM L-glutamine (Gibco BRL) and 
supplemented with 10% bovine foetal serum (Gibco 
BRL), antibiotics (100,000 IU/ml penicilin/10,000 pglml 
streptomycin) (Gibco BRL) and 10 mM Hepes (Gibco 
BRL) in a humidified 5% C02  atmosphere at 37 "C. 
Cells were seeded onto sterile glass slides in petri 
dishes to establish 4 study groups: Group 1, SMC 
cultured in F-12 medium alone; Group 11, SMC seeded 
on a VN substrate (5 pgíml; SIGMA); Group 111, SMC 
seeded on VN (5 pg/ml) and incubated with the P37 
monoclonal antibody (200 nM); and Group IV, SMC 
incubated with P37 (200 nM The density of seeding k was 5 x 1 0 ~  cells per 3.14 cm surface area in 1 m1 of 
culture medium. Cells were left to grow for 48 h until 
stable and then incubated for 4 days while subjected to 
the different treatments. 
Morphological identification 
Smooth muscle cel ls  were identified by 
immunocytochemistry using the smooth muscle anti-a 
actin (SIGMA) and total anti-actin (a gift from Dr. 
Gabianni) primary antibodies, both specific for SMC. 
Labelling was performed using cells fixed in methanol at 
-20 "C for 5 min. Rabbit anti-mouse IgG (Zymed 
Laboratories Inc., CA, USA) and goat anti-rabbit IgG 
(Nordic) antibodies diluted 1/20 in PBS, pH 7.6 
conjugated with FITC were used a s  secondary 
antibodies. Labelled specimens were examined using a 
Zeiss Axiophot microscope equipped with a 
fluorescence lamp. Cell images were taken using 
Fujichrome 400 film (Fuji Photo Film Co., Ltd., Tokyo). 
Cell proliferation assays 
After  the corresponding 4-day treatment, the 
cultured SMC were washed and incubated with 3 ~ -  
thymidine (2 pCilml) for a further 6 h. Cultures were 
then washed and subjected to autoradiography on the 
same day. In brief, glass slides were submerged in a 
(1: l )  water dilution of the radiographic emulsion 
(NTBP-2, Eastman Kodak, Rochester, NY) at 40 "C and 
kept in the dark for 2 weeks at 4 "C. Glass slides were 
developed in D-19 (Kodak) for 5 min with agitation. 
Following a brief rinse in 0.5% acetate, cells were fixed 
with Rapid Fix (Kodak) for a further 5 min, washed for 
1 h in running water and left to dry at room temperature. 
The SMC were stained with Carrazzi haematoxylin and 
mounted. 
Cell migration assays 
After 4 days of treatment, the edge of the cultures 
was traced and the dispersion area determined using 
software adapted for computerised image analysis 
(Optimas 6.5 for Windows, Data Cell Ltd., UK). 
In situ DNA fragmentation 
The in vitro identification of apoptotic cells was 
performed by modification of the TUNEL method 
(Negoescu et al., 1996). This method is based on the in 
s i tu  detection of fragmented nucleosomal DNA 
characteristic of apoptosis by the specific binding of 
deoxynucleotides to the exposed 3-OH-ends of the 
fragmented chromatin. Specimens were subjected to 
microwave irradiation (SANYO EM-704T) for 5 min 
(350W) in 0.01M citrate buffer (pH 6). Fragmented 
DNA was  determined using a commercial kit  
(Calbiochem, CN Biosciences Inc., USA). 
Cell viabilify 
The number of viable cells was determined by 
trypan blue exclusion and counted in a Neubauer 
chamber. 
Statistical analysis 
Proliferation and migration data were expressed as 
means 2 standard deviation. The Mann-Whitney U-test 
was used to compare data corresponding to the different 
treatments. The leve1 of significance was set at pe0.05. 
Results 
Morphological analysis 
Changes in cell morphology produced during the 4 
Flg. 1. Morphological findings of SMC cultui 
SMC control (A, B), SMC seeded onto VN ( 
P37 [200 nM] (G, H). 
3xpression of a-smooth muscle actin (A, C, E, G) (x 63) and cell shape appearance (8, D, F, H) ( ). 
), SMC incubated in the presence of P37 [200 nM] (E, F) and SMC seeded onto VN and incubated with 
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days of culture were monitored in the different treatment 
groups. Control SMC incubated in F-12 medium alone 
showed the typical muscle cell morphology including 
extensive cytoplasm and a high density of 
microfilaments (Fig. l a ) .  The presence of these 
microfilaments was confirmed using the smooth muscle 
anti-a actin antibody. Cultures showed an even 
distribution on the glass slide (Fig. lb). When cells were 
grown in the presence of the VN substrate (Fig. lc), this 
typical morphology was maintained although punctate 
areas of increased cell density were observed (Fig. Id). 
The addition of P37 to the culture medium in the 
absence of VN led to changes in cell architecture 
including the observation of retracted cells that had lost 
the ability to adhere to the substrate, loss of actin 
microfilaments (Fig. l e ) ,  and changes in cell 
organisation giving rise to areas of low cell density (Fig. 
lf). The combined use of VN and P37 induced similar 
cell behaviour to that observed in the presence of P37 
alone, with cells lacking the morphology of control SMC 
(Fig. lg)  and a failure to form homogenous cultures 
(Fig. lh). 
Cell proliferation 
The autoradiograph demonstrated the proliferative 
capacity of the cultures and permitted the determination 
of growth rates expressed as the number of proliferating 
cells per thousand. SMC grown in the absence 
(10.26k2.26) or presence (14.4720.24) of VN showed 
similar progression although VN favoured growth such 
that at 4 days of incubation, significant differences were 
recorded between these groups. However, the sole 
presence of the antibody against the P37 83 subunit 
caused the total arrest of cell growth (0+0). In the 
Cell migration 
Flg. 2. The figure illustrate the cell dispersion in the presencelabsence 
of VN as grown substrate and P37 as treatment. 
combined presence of VN and the P37 antibody, the 
growth rate increased to 2.6 20.75. 
Cell migration 
The dispersion area of the SMC cultures (Fig. 2) was 
increased compared to that of control cultures in the 
presence of the VN substrate. The presence of P37 (200 
nM) in the culture medium led to a reduction in the cell 
dispersion area that attained a difference of 50% with 
respect to control cultures. The combined presence of 
VN and P37 had no effect on the cell migration observed 
in the independent presence of the P37 antibody. 
Cell damage 
Owing to an insufficient number of cells in cultures 
grown (Fig. 3) in the presence of the P37 antibody, we 
were unable to detect a significant difference in the 
proportion of apoptotic cells between groups using the 
TUNEL procedure. Labelled cells were detected in al1 
the groups but this was probably the result of the 
experimental conditions of culture. 
Discussion 
In a previous study, we were able to show that the 
P37 antibody is able to delay but not inhibit the 
appearance of intima1 hyperplasia in an in vivo model 
(Buján et al., 1997). Here, we demonstrate that this 
antibody directed towards the avg3  integrin, is an 
inhibitor of in vitro SMC proliferation and migration and 
that the latter is dependent upon the presence of ligands 
such as VN that are able to bind the antibody. 
To date, numerous molecules have been used as 
inhibitors of certain integrins with the sole purpose of 
inhibiting the phenomenon of SMC migration and thus 
the progression of the intima (Matsuno et al., 1994; 
Cell viability 
1 2 3 4 days 
-e- Control + VN +- P37 -m- VN+P37 
Fig. 3. Smooth muscle cell viability deterrnined by trypan blue staining. 
Note the decrease in the nurnber of cells when P37 is added to the 
culture medium. 
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Buján et al., 1997; Itoh et al., 1997). Many of these 
substances are antibodies against the fibrinogen receptor 
(aIIbB3) and are not always capable of blocking other 
molecules such as the vitronectin receptor (avg3) - with 
the exception of ReoPro (Coller et al., 1991) - such that 
their in vivo effects differ according to the molecules 
they block (Felding-Habermann and Cheresch, 1993; 
Clyman et al., 1994; Coller et al., 1995). Apoptotic 
effects on proliferating cells induced by integrin avg3- 
blocking antibodies such that they act as modulators of 
tumour progression (Brooks et al., 1994) have 
occasionally been described. We were unable to 
demonstrate the presence of apoptotic cells although this 
analysis was performed after 4 days of incubation with 
the different treatments. It is likely that cell damage 
occurs at an earlier stage, given that in experiments 
performed in vivo with this antibody, we were indeed 
able to detect the presence of TUNEL-positive SMC 
(data not shown). 
In order to evaluate the capacity of these 
experimental antibodies to inhibit  myointimal 
progression, severa1 authors have analysed their effects 
on adhesion and migration phenomena of the SMC. The 
use of different growth substrates has been reported 
including VN as a stimulator of SMC migration 
regulated by B3 integrins (Brown et al., 1994; Jones et 
al., 1995) and collagen for B 1  integrins (Gotwals et al., 
1996). The resulting data permitted the determination of 
which type of integrins specifically mediated adhesion 
(01, 83 and B5) or migration (83) (Liaw et al., 1995), 
expanding knowledge on the role of the 03 subunit in 
both these processes. The P37 antibody used in the 
present study is specific for this B3 subunit, hence the 
evaluation of its in vitro effects on SMC should give us 
some idea of its efficiency in vivo. 
Our finding of increased SMC proliferation in the 
presence of VN is consistent with the findings of Jones 
et al. (1996). The higher migration values reported here 
may be the result of different analytical criteria; we 
determined the area of cell migration while Jones et al. 
estimated the number of migrating cells. 
The increase in both S M C  proliferation and 
migration induced on the VN substrate provides support 
for a relevant role of a v g 3  in both these processes. 
Further, the capacity of the P37 antibody to inhibit cell 
proliferation is a clear indication of the participation of 
B3 integrin in this phenomenon and a possible 
explanation for previous in vivo observations. In this 
situation, the antibody is able to block the receptors of 
platelet adhesion to the subendothelial matrix that 
becomes exposed after injury and thus inhibit  
thrombosis phenomena delaying the appearance of the 
neointimal layer (Bujan et al., 1997). The present 
findings demonstrate the participation of the P37 
antibody in yet another process involved i n  the 
development of hyperplasia. We were able to show that 
P37 is able to block the 83 subunit on the SMC as well 
as the platelet, thus inhibiting the proliferation and 
migration of these cells from the media1 layer to the site 
of injury and delaying the formation of a proliferative 
layer that would eventually lead to vascular occlusion. 
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